GlassScriptPhysician profile
Aravind R Sanjeevaiah
NPI 1093913196
$1,694.01
in general payments reported to CMS, 2019-2025
14 companies · $265 in 2025
The $265 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,105 · 2023: $114 · 2024: $210 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $589.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,115.44 | 2019-2024 | Jakafi |
| Pfizer INC. | $113.50 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $107.71 | 2024-2025 | Opdivo |
| Sumitomo Pharma America, INC. | $102.42 | 2024 | Orgovyx |
| Astellas Pharma US INC | $93.03 | 2023 | |
| Novartis Pharmaceuticals Corporation | $39.45 | 2023-2024 | |
| Gilead Sciences, INC. | $38.32 | 2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $25.33 | 2025 | Enhertu |
| Tersera Therapeutics LLC | $24.01 | 2025 | Zoladex |
| Caris Mpi, INC. | $17.99 | 2025 | Mi Cancer Seek |
| Amgen INC. | $16.81 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aravind Sanjeevaiah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.